These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 31286275)
1. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm. Weiner AB; Nettey OS; Morgans AK Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275 [TBL] [Abstract][Full Text] [Related]
2. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF; Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492 [TBL] [Abstract][Full Text] [Related]
3. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421 [TBL] [Abstract][Full Text] [Related]
6. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan. Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153 [TBL] [Abstract][Full Text] [Related]
7. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976 [TBL] [Abstract][Full Text] [Related]
8. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer]. Wenzel M; Hoeh B; Chun FKH; Mandel P Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112 [TBL] [Abstract][Full Text] [Related]
9. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790 [TBL] [Abstract][Full Text] [Related]
10. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Hoeh B; Garcia CC; Wenzel M; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH; Mandel P Eur Urol Focus; 2023 Sep; 9(5):838-842. PubMed ID: 37055323 [TBL] [Abstract][Full Text] [Related]
11. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300 [TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644 [TBL] [Abstract][Full Text] [Related]
13. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Mandel P; Hoeh B; Wenzel M; Preisser F; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Chun FKH Eur Urol Focus; 2023 Jan; 9(1):96-105. PubMed ID: 36058809 [TBL] [Abstract][Full Text] [Related]
14. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. Mutlu H; Bozcuk H J Cancer Res Ther; 2023; 19(2):394-402. PubMed ID: 37313915 [TBL] [Abstract][Full Text] [Related]
15. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737 [TBL] [Abstract][Full Text] [Related]
16. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation. Xu L; Pachynski RK Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573 [TBL] [Abstract][Full Text] [Related]
17. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754 [TBL] [Abstract][Full Text] [Related]
18. [Treatment concepts for primary oligometastatic prostate cancer]. Knipper S; Graefen M; Hadaschik B; Wiegel T Urologe A; 2020 Jun; 59(6):659-664. PubMed ID: 32274541 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Lage DE; Michaelson MD; Lee RJ; Greer JA; Temel JS; Sweeney CJ Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1181-1188. PubMed ID: 34007017 [TBL] [Abstract][Full Text] [Related]
20. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Kyriakopoulos CE; Chen YH; Carducci MA; Liu G; Jarrard DF; Hahn NM; Shevrin DH; Dreicer R; Hussain M; Eisenberger M; Kohli M; Plimack ER; Vogelzang NJ; Picus J; Cooney MM; Garcia JA; DiPaola RS; Sweeney CJ J Clin Oncol; 2018 Apr; 36(11):1080-1087. PubMed ID: 29384722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]